

Global Congenital Adrenal Hyperplasia Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, Trends

Congenital Adrenal Hyperplasia Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 25, 2025
/EINPresswire.com/ -- Updated 2025
Market Reports Released: Trends, Forecasts to 2034 – Early Purchase
Your Competitive Edge Today!



The Business
Research Company

The Business Research Company

Will the [Congenital Adrenal Hyperplasia Market](#) Continue to See Impressive Growth?



The congenital adrenal hyperplasia market size is expected to see strong growth in the next few years. It will grow to \$0.66 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%.”

*The Business Research
Company*

The global congenital adrenal hyperplasia market is witnessing a robust growth pattern. The market size that stood at \$0.47 billion in 2024 is expected to touch the \$0.50 billion mark by 2025, registering a compound annual growth rate CAGR of 7.3%. The surge during the historic period has been driven by the increasing prevalence of congenital adrenal hyperplasia, higher acceptance of corticosteroid therapies, growing healthcare expenditure, priority given to pediatric health care, as well as extensive government initiatives and extensive reimbursement policies.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample_request?id=21157&type=smp

Will Gene Therapy Drive the [Congenital Adrenal Hyperplasia Market Forward](#)?

What's more, market prospects for the next few years look promising. By 2029, the congenital adrenal hyperplasia market is projected to grow to \$0.66 billion, indicating a CAGR of 7.1%. Key

factors contributing to this forecast period growth encompass burgeoning demand for personalized medicine, increased occurrences of genetic disorders, growing investments in research focused on congenital adrenal hyperplasia treatments, rising healthcare investments, and a marked rise in the use of telemedicine for managing congenital adrenal hyperplasia. Other important trends surfacing in this forecast period include advancements across healthcare infrastructure, molecular diagnostics innovation, the development of enzyme replacement therapies, the emergence of long-acting corticosteroid formulations, as well as groundbreaking progress in genetic screening.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/congenital-adrenal-hyperplasia-global-market-report>

Who are the Major Players in the Congenital Adrenal Hyperplasia Market?

The congenital adrenal hyperplasia market teems with several significant players. These include Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., and Crinetics Pharmaceuticals Inc.

What Innovative Treatments are being Developed by Companies?

In the recent years, companies operating in the congenital adrenal hyperplasia marketplace have taken a pivot towards developing cutting-edge treatments such as CRF1 receptor antagonists. These are crucial in regulating cortisol production and controlling adrenal androgen excess. As an example, Neurocrine Biosciences, Inc, received FDA approval in December 2024 for a first-of-its-kind, new treatment for congenital adrenal hyperplasia CAH in 70 years. Known as crenessity crinecerfont, these oral medicines function as selective antagonists of corticotropin-releasing factor type 1 receptors. Such drugs can manage adrenocorticotrophic hormone ACTH excess and adrenal androgens efficiently, while also facilitating a reduction in glucocorticoid doses. The approval came on the back of significant data from the CAHtalyt Phase 3 studies, which demonstrated a significant effect in reducing androgen levels. The drug is expected to make its way to the markets soon and is hailed as a significant advancement in the management of CAH.

How is the Congenital Adrenal Hyperplasia Market Segmented?

To offer better insights, the report segments the congenital adrenal hyperplasia market by type into Classic Congenital Adrenal Hyperplasia and Non-Classic Congenital Adrenal Hyperplasia. Additionally, it categorizes by Treatment And Diagnosis into Diagnosis and Treatment, and by

End-Use as Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Research Institutes.

The sub-segments breakdown is as follows:

By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia, Simple Virilizing Classic Congenital Adrenal Hyperplasia, and by Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia, Mild Non-Classic Congenital Adrenal Hyperplasia.

Where is the [Congenital Adrenal Hyperplasia Global Market](#) seeing the most growth?

In 2024, North America was the dominant region for the congenital adrenal hyperplasia market. However, Asia-Pacific is expected to register the fastest growth in the upcoming forecast period. The report provides comprehensive coverage of the market in Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Congenital Diaphragmatic Hernia Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report>

Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report>

Adrenal Cancer Diagnostics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/adrenal-cancer-diagnostics-global-market-report>

About The Business Research Company:

The Business Research Company, with its vast collection of 15,000+ reports spanning 27 unique industries and covering 60+ diverse geographies, has established itself as a trusted provider of extensive and comprehensive, data-centric research and insights. With a colossal database of 1,500,000 datasets, in-depth secondary research capacities, and unique insights derived from elite industry leaders, The Business Research Company is your ultimate source of trusted information that can help you maintain your competitive advantage.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/796909723>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.